These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
47. KIT and PDGFRA mutations in gastrointestinal stromal tumors (GISTs). Lasota J; Miettinen M Semin Diagn Pathol; 2006 May; 23(2):91-102. PubMed ID: 17193822 [TBL] [Abstract][Full Text] [Related]
48. Treatment of gastrointestinal stromal tumor after imatinib and sunitinib. Montemurro M; Bauer S Curr Opin Oncol; 2011 Jul; 23(4):367-72. PubMed ID: 21519258 [TBL] [Abstract][Full Text] [Related]
49. KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients. Gajiwala KS; Wu JC; Christensen J; Deshmukh GD; Diehl W; DiNitto JP; English JM; Greig MJ; He YA; Jacques SL; Lunney EA; McTigue M; Molina D; Quenzer T; Wells PA; Yu X; Zhang Y; Zou A; Emmett MR; Marshall AG; Zhang HM; Demetri GD Proc Natl Acad Sci U S A; 2009 Feb; 106(5):1542-7. PubMed ID: 19164557 [TBL] [Abstract][Full Text] [Related]
50. Gastrointestinal stromal tumor: advances in diagnosis and management. Patil DT; Rubin BP Arch Pathol Lab Med; 2011 Oct; 135(10):1298-310. PubMed ID: 21970485 [TBL] [Abstract][Full Text] [Related]
51. Treatment of wild-type gastrointestinal stromal tumor (WT-GIST) with imatinib and sunitinib. Murray M; Hatcher H; Jessop F; Williams D; Carroll N; Bulusu R; Judson I Pediatr Blood Cancer; 2008 Feb; 50(2):386-8. PubMed ID: 17729245 [TBL] [Abstract][Full Text] [Related]
52. Current and emerging pharmacological treatments for gastrointestinal stromal tumour. Ganjoo KN; Patel S Drugs; 2011 Feb; 71(3):321-30. PubMed ID: 21319869 [TBL] [Abstract][Full Text] [Related]
53. Response to imatinib in KIT- and PDGFRA-wild type gastrointestinal stromal associated with neurofibromatosis type 1. Lee JL; Kim JY; Ryu MH; Kang HJ; Chang HM; Kim TW; Lee H; Park JH; Kim HC; Kim JS; Kang YK Dig Dis Sci; 2006 Jun; 51(6):1043-6. PubMed ID: 16865565 [No Abstract] [Full Text] [Related]
54. Clinical implications of KIT and PDGFRA genotyping in GIST. Martín-Broto J; Rubio L; Alemany R; López-Guerrero JA Clin Transl Oncol; 2010 Oct; 12(10):670-6. PubMed ID: 20947481 [TBL] [Abstract][Full Text] [Related]
56. Neoadjuvant use of sunitinib in locally advanced GIST with intolerance to imatinib. Svetlichnaya J; Huyck TK; Wayne JD; Agulnik M Chemotherapy; 2012; 58(1):30-3. PubMed ID: 22415035 [TBL] [Abstract][Full Text] [Related]
58. Cost effectiveness of tyrosine kinase inhibitor therapy in metastatic gastrointestinal stromal tumors. Blanke CD; Huse DM J Med Econ; 2010; 13(4):681-90. PubMed ID: 21067355 [TBL] [Abstract][Full Text] [Related]
59. Implications of mutational analysis for the management of patients with gastrointestinal stromal tumors and the application of targeted therapies. Wozniak A; Floris G; Debiec-Rychter M; Sciot R; Schöffski P Cancer Invest; 2010 Oct; 28(8):839-48. PubMed ID: 20690803 [TBL] [Abstract][Full Text] [Related]
60. [Gastrointestinal stromal tumour (GIST): current standards in multimodal management]. Reichardt P; Reichardt A Zentralbl Chir; 2011 Aug; 136(4):359-63. PubMed ID: 21863513 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]